Page last updated at 13:29 GMT, Saturday, 3 April 2010 14:29 UK

Too many new cancer drugs turned down, Tories say

By Branwen Jeffreys
Health correspondent, BBC News

Drug pills and containers
NICE advises on which drugs should be bought by the NHS

Too many new cancer drugs are being turned down or restricted to small groups of NHS patients in England, the Conservatives claim.

Shadow health secretary Andrew Lansley said doctors should have a greater role in deciding which drugs to prescribe.

The party is calling for better deals with manufacturers to reduce prices.

But the government's medicines advisory body said it recommended drugs backed by clinical evidence, targeted at patients most likely to benefit.

On Saturday, Conservative leader David Cameron met with campaigners for kidney cancer drugs in his home constituency of Witney, Oxfordshire, where he outlined a plan for a cancer drugs fund.

He said since a Tory government would not go ahead with Labour's planned National Insurance increase, the £200m this would cost the NHS would instead be used to provide more people with drugs.

"We want to get drugs together more quickly," he said.

"In the UK today there are thousands of people who want a certain cancer drug, whose doctors tell them they should have one, who don't get it."

Balance of decisions

The Department of Health said in a statement that the Conservative analysis was "selective" and "misleading".

A spokesman added: "Cancer is frightening to face, tough to beat and it is important to have clear information rather than this selective way of representing data".

Not all patients with a particular condition benefit from a drug and some drugs only work really well for some patients or at a particular stage in a disease
Sir Andrew Dillon

The Tories said they were not criticising individual decisions made by the National Institute of Health and Clinical Excellence (NICE), but wanted to see a shift in the balance of decisions.

Mr Lansley said: "We've got to arrive at a point where people who have a cancer, who know there is a new cancer medicine that sometimes is clearly shown to extend life, or improve the quality of life, and their prospects, that those drugs are going to be available on the NHS."

But the chief executive of NICE, Sir Andrew Dillon, said it was wrong to recommend the use of treatments "where the additional benefit is uncertain".

"Not all patients with a particular condition benefit from a drug and some drugs only work really well for some patients or at a particular stage in a disease," he said.


Decisions on whether to recommend a drug for certain stages of a disease or for certain patients were often based on information from the European Medicines Agency, the drugs watchdog added.

The Conservatives are also calling for greater use of patient access schemes, where a drugs manufacturer typically agrees to discount the price of a new cancer treatment for certain types of patient.

How this would be achieved is unclear, as the NHS is only a small part of the global market for a new drug. At the moment NICE can only consider such schemes if they are proposed by the manufacturer.

Since November 2008, NICE has considered 14 new treatments for cancer and approved nine of them for use by NHS patients. In some cases, the drugs under consideration were to treat the same type of cancer.

A drug for advanced kidney cancer, Sutent, was recommended as the first treatment for patients in March 2009 after a vigorous campaign by doctors and patients.

But three other drugs for the same type of cancer have had their application to be used as a first line treatment turned down by NICE.

Print Sponsor

Experts in drug 'ration' warning
24 Aug 08 |  Health
Row over NHS kidney drug decision
07 Aug 08 |  Health
'We'll sell our house for this drug'
07 Aug 08 |  Health
Drug decision 'bad for patients'
07 Aug 08 |  Manchester
NHS Postcode Lottery: It Could Be You
15 Aug 08 |  Panorama
Man 'disgusted' by drug decision
07 Aug 08 |  Bradford

The BBC is not responsible for the content of external internet sites

Has China's housing bubble burst?
How the world's oldest clove tree defied an empire
Why Royal Ballet principal Sergei Polunin quit


Americas Africa Europe Middle East South Asia Asia Pacific